Variant ALK-fusion positive anaplastic large cell lymphoma (ALCL): A population-based paediatric study of the NHL-BFM study group.
ALK positive ALCL
non-Hodgkin's lymphoma
variant ALK
Journal
British journal of haematology
ISSN: 1365-2141
Titre abrégé: Br J Haematol
Pays: England
ID NLM: 0372544
Informations de publication
Date de publication:
26 Jan 2024
26 Jan 2024
Historique:
revised:
08
12
2023
received:
02
11
2023
accepted:
10
01
2024
medline:
27
1
2024
pubmed:
27
1
2024
entrez:
27
1
2024
Statut:
aheadofprint
Résumé
Frequency, distribution and prognostic meaning of ALK-partner genes other than NPM1 in ALK-positive anaplastic large-cell lymphoma (ALCL) are unknown. Forty-nine of 316 ALCL diagnosed in the NHL-BFM study group showed no nuclear ALK expression suggestive of a variant ALK-partner; 41 were analysed by genomic capture high-throughput sequencing or specific RT-PCRs. NPM1::ALK was detected in 13 cases. Among the 28 patients with a non-NPM1::ALK-fusion partner, ATIC (n = 8; 29%) and TPM3 (n = 9; 32%) were the most common. Five of eight patients with ATIC::ALK-positive ALCL relapsed, none of nine with TPM3::ALK. Variant ALK-partners are rare and potentially associated with different prognoses.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Hamburger Stiftung zur Foerderung der Krebsbekaempfung
Organisme : Juli Harnack scholarship of the Foerdergemeinschaft Kinderkrebszentrum Hamburg e.V.
Organisme : KinderkrebsInitiative Buchholz, Holm-Seppensen
Organisme : Deutsche Kinderkrebsstiftung
Informations de copyright
© 2024 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.
Références
Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IBO, Berti E, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia. 2022;36(7):1720-1748.
Elenitoba-Johnson KS, Ott G, Takeuchi K, Klapper W, Lamant-Rochaix L, d'Amore ESG, et al. ALK-positive anaplastic large cell lymphoma. WHO classification of tumours editorial board Haematolymphoid tumours. Volume 11. 5th ed. Lyon (France): WHO Classification of Tumours Series, International Agency for Research on Cancer; 2022 [cited 2023 Oct 20]. Available from: https://tumourclassification.iarc.who.int/chapters/63
Falini B, Pulford K, Pucciarini A, Carbone A, De Wolf-Peeters C, Cordell J, et al. Lymphomas expressing ALK fusion protein(s) other than NPM-ALK. Blood. 1999;94(10):3509-3515.
Stein H, Foss HD, Durkop H, Marafioti T, Delsol G, Pulford K, et al. CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. Blood. 2000;96(12):3681-3695.
Benharroch D, Meguerian-Bedoyan Z, Lamant L, Amin C, Brugieres L, Terrier-Lacombe MJ, et al. ALK-positive lymphoma: a single disease with a broad spectrum of morphology. Blood. 1998;91(6):2076-2084.
Falini B, Bigerna B, Fizzotti M, Pulford K, Pileri SA, Delsol G, et al. ALK expression defines a distinct group of T/null lymphomas ("ALK lymphomas") with a wide morphological spectrum. Am J Pathol. 1998;153(3):875-886.
Perkins SL, Pickering D, Lowe EJ, Zwick D, Abromowitch M, Davenport G, et al. Childhood anaplastic large cell lymphoma has a high incidence of ALK gene rearrangement as determined by immunohistochemical staining and fluorescent in situ hybridisation: a genetic and pathological correlation. Br J Haematol. 2005;131(5):624-627.
Damm-Welk C, Klapper W, Oschlies I, Gesk S, Rottgers S, Bradtke J, et al. Distribution of NPM1-ALK and X-ALK fusion transcripts in paediatric anaplastic large cell lymphoma: a molecular-histological correlation. Br J Haematol. 2009;146(3):306-309.
Lamant L, McCarthy K, D'Amore E, Klapper W, Nakagawa A, Fraga M, et al. Prognostic impact of morphologic and phenotypic features of childhood ALK-positive anaplastic large-cell lymphoma: results of the ALCL99 study. J Clin Oncol. 2011;29(35):4669-4676.
Armstrong F, Duplantier MM, Trempat P, Hieblot C, Lamant L, Espinos E, et al. Differential effects of X-ALK fusion proteins on proliferation, transformation, and invasion properties of NIH3T3 cells. Oncogene. 2004;23(36):6071-6082.
Armstrong F, Lamant L, Hieblot C, Delsol G, Touriol C. TPM3-ALK expression induces changes in cytoskeleton organisation and confers higher metastatic capacities than other ALK fusion proteins. Eur J Cancer. 2007;43(4):640-646.
van der Krogt JA, Bempt MV, Ferreiro JF, Mentens N, Jacobs K, Pluys U, et al. Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma with the variant RNF213-, ATIC- and TPM3-ALK fusions is characterized by copy number gain of the rearranged ALK gene. Haematologica. 2017;102(9):1605-1616.
Ma Z, Hill DA, Collins MH, Morris SW, Sumegi J, Zhou M, et al. Fusion of ALK to the ran-binding protein 2 (RANBP2) gene in inflammatory myofibroblastic tumor. Genes Chromosomes Cancer. 2003;37(1):98-105.
Pulford K, Lamant L, Espinos E, Jiang Q, Xue L, Turturro F, et al. The emerging normal and disease-related roles of anaplastic lymphoma kinase. Cell Mol Life Sci. 2004;61(23):2939-2953.
Wehkamp U, Oschlies I, Nagel I, Brasch J, Kneba M, Gunther A, et al. ALK-positive primary cutaneous T-cell-lymphoma (CTCL) with unusual clinical presentation and aggressive course. J Cutan Pathol. 2015;42(11):870-877.